Triplet Does Not Improve Survival in Prostate Cancer January 3, 2017 Adding Xtandi to Zytiga and prednisone did not improve progression-free survival for patients with metastatic castration-resistant prostate cancer, according to a recent study. Read more.Source: CURE Magazine Prostate Cancer News
Adding Xtandi to Zytiga and prednisone did not improve progression-free survival for patients with metastatic castration-resistant prostate cancer, according to a recent study. Read more.Source: CURE Magazine
Donate Now
